No Data
Express News | Shandong Sanyuan Biotechnology Says Impact of U.S. Move on Co's Production and Operation Uncertain; Co Will Closely Monitor Any Development
Express News | Shandong Sanyuan Biotechnology Says Co Has Set up Special Work Team in Response to Cargill's Investigation Request to U.S. Over Erythritol Products Imported From China
Sanyuan Biological (301206.SZ): "The project for the annual production of 50,000 tons of erythritol and technology center has been completed and the remaining raised funds will be permanently used to supplement working capital."
On December 16, Gelonghui reported that Sanyuan Bio (301206.SZ) held the fourth meeting of the fifth Board of Directors and the fourth meeting of the fifth Supervisory Board on December 16, 2024, and reviewed and approved the proposal on the completion of some fundraising projects and the permanent supplementation of surplus funds into working capital. It was agreed to conclude the fundraising project for the initial public offering of Stocks "Annual production of 50,000 tons of erythritol and technology center project," and to allocate the surplus raised funds of 352.2712 million yuan (including payables for contract balances, warranty funds, and interest already received or receivable after deducting handling fees.
Sanyuan Biological (301206.SZ): The company currently has no plans to acquire a starch enterprise.
According to Gelonghui on December 6, San Yuan Biology (301206.SZ) stated on the investor interaction platform that the company maintains long-term stable cooperation with multiple starch enterprises within the province, which can fully meet the current production needs. As of now, the company has no plans to acquire starch enterprises. If there are related matters, the company will strictly fulfill its information disclosure obligations according to laws and regulations.
Sanyuan Bio (301206.SZ): has repurchased a total of 0.26% of shares.
On December 2, Gelonghui announced that as of November 30, 2024, Sanyuan Bioscience (301206.SZ) disclosed that the company repurchased a total of 525,700 shares through a share buyback dedicated account in a centralized competitive bidding trading method, accounting for 0.26% of the total share capital. The highest fill price was 27.78 yuan per share, the lowest fill price was 23.70 yuan per share, and the total fill amount was 12.9113 million yuan (excluding transaction costs).
Sanyuan Biological (301206.SZ): Currently has a production capacity of 10,000 tons of allulose per year.
On November 27, Gelonghui reported that Three Trees Bioscience (301206.SZ) stated on the investor interaction platform that the company currently has an annual production capacity of 10,000 tons of allose, which can well meet the diversified market demand.
No Data
